In recent years, the landscape of infectious disease research has undergone a transformative shift, driven by the advent of sophisticated experimental models that recapitulate human tissue complexity with unprecedented fidelity. Among these, human organoids—three-dimensional, stem cell-derived mini-organs—have emerged as pivotal tools in unraveling the intricate dynamics of pathogenic infections. These in vitro platforms transcend the limitations of traditional two-dimensional cell cultures and animal models, which often fail to accurately mimic human-specific disease pathophysiology. As a consequence, organoids are gaining traction for their capacity to shed light on organ-specific infections, facilitating the exploration of viral pathogenesis with nuanced detail.
Endemic and emerging infectious diseases continue to present formidable challenges to public health systems worldwide, not only due to their high morbidity and mortality but also because of the complex interplay between pathogens and host tissues. Viral pathogens, in particular, exploit highly specialized cellular environments and immune evasive strategies that are difficult to model ex vivo. Organoid technology, leveraging stem cell pluripotency and differentiation pathways, offers a transformative approach to reproducing the cellular heterogeneity and microenvironmental context of human organs. This fidelity is critical when dissecting infection mechanisms, viral tropism, replication dynamics, and host immune responses.
The versatility of organoid platforms is evident across numerous physiological systems implicated in infectious diseases. In the respiratory system, for example, airway and alveolar organoids have elucidated key aspects of viral entry and replication for pathogens such as influenza virus and SARS-CoV-2. These models incorporate relevant epithelial cell types and extracellular matrix components, enabling researchers to observe viral spread and cytopathic effects in a controlled yet physiologically relevant framework. Beyond the respiratory tract, gastrointestinal organoids derived from intestinal epithelium have been instrumental in modeling infections by noroviruses and rotaviruses, revealing insights into viral persistence and mucosal immunity.
The nervous system represents another frontier where organoids have unveiled novel insights into neurotropic viral infections. Brain organoids, recapitulating cortical structures, have provided platforms to study Zika virus-induced microcephaly and herpes simplex virus neuropathogenesis. These systems allow for observation of viral impact on neurodevelopmental processes and neuronal network integrity, which remain challenging to assess in vivo due to ethical and technical constraints. Furthermore, cardiac and vascular organoids facilitate investigation of viral myocarditis and endothelial dysfunction caused by emerging viruses, highlighting the systemic ramifications of infections.
To further enhance the biological relevance of organoids, researchers are developing immune-competent and vascularized models. Incorporation of immune cells such as macrophages, dendritic cells, and lymphocytes enables the study of host-pathogen interactions in a context that approximates in vivo immune surveillance and response. Vascularization, achieved through co-culture methods or bioengineering techniques, is vital for studying nutrient exchange, immune cell trafficking, and pathogen dissemination. These advanced organoid systems bridge the gap between static models and the dynamic complexity of living tissues, providing insights into infection-induced inflammation and tissue remodeling.
Innovative organoid-on-a-chip technologies represent an evolution in this domain, integrating microfluidic devices with organoid cultures to simulate blood flow, mechanical forces, and inter-organ communication. These platforms facilitate real-time monitoring of infection kinetics and therapeutic responses under physiologically relevant conditions. They enable multiplexed analysis of multi-organ infection scenarios, such as viral spread from the respiratory tract to the gastrointestinal system or brain, thereby enhancing our understanding of pathogen dissemination and tropism.
Beyond basic research applications, organoid platforms are rapidly becoming indispensable for vaccine and antiviral drug development. These models allow for testing of candidate vaccines in human-relevant tissues, assessing immunogenicity and efficacy in a microenvironment that reflects human biology. Antiviral therapeutics can be evaluated for their ability to inhibit viral replication or mitigate tissue damage within organoids, accelerating the translation of preclinical findings. Moreover, organoids can model genetic variability among human populations, refining personalized medicine approaches to infectious disease management.
Additionally, organoid technology plays a crucial role in studying zoonotic transmission—the spillover of pathogens from animal reservoirs to humans—by enabling cross-species infection modeling. This capability facilitates the identification of viral adaptations essential for human infectivity and supports the detection of potential pandemic threats at an early stage. As a consequence, organoids are poised to become central components in global pandemic preparedness strategies, enhancing pathogen surveillance and rapid response capabilities.
Despite their promise, challenges remain in organoid-based infectious disease research. Enhancing tissue-like complexity and maturity within organoids is essential to faithfully replicate adult human organ physiology. Current hurdles include achieving full differentiation, multicellular composition, and functional integration of immune and non-parenchymal cell types. Standardization of organoid culture protocols and assays is equally critical to ensure reproducibility across laboratories, enabling robust comparative studies.
Scalability and throughput are other vital considerations, particularly for high-throughput drug screening applications. Advances in automation, miniaturization, and bioprinting technologies are expected to drive improvements in production efficiency and experimental scalability. Moreover, integration of omics technologies with organoid platforms promises deeper molecular characterization of infection processes and host responses, further enriching the pathogenic landscape.
In conclusion, human organoids represent a paradigm shift in infectious disease research, offering unprecedented opportunities to model complex, organ-specific infections with high physiological and pathological relevance. Their integration into virology studies is propelling the field beyond traditional limitations, enabling more precise elucidation of viral mechanisms and host-pathogen interactions. As technological refinements continue, organoid platforms will undoubtedly accelerate the discovery of novel therapeutics, vaccines, and preventive strategies, bolstering our capacity to combat infectious diseases in an increasingly interconnected world.
Subject of Research: Organoids as experimental platforms for studying viral infectious diseases.
Article Title: Organoids as platforms for infectious disease research.
Article References:
Liu, K., Zhao, Y., Joloya, E.M. et al. Organoids as platforms for infectious disease research. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00445-3
Image Credits: AI Generated
DOI: 10.1038/s44222-026-00445-3
Keywords: human organoids, infectious disease models, viral pathogenesis, respiratory infections, gastrointestinal infections, neurotropic viruses, immune-competent organoids, vascularized organoids, organoid-on-a-chip, vaccine development, antiviral therapeutics, zoonotic transmission, pandemic preparedness
